Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.

A Double-Blind, Placebo-Controlled, Randomized, 18-Month Phase 2A Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of Oral UCB0599 in Study Participants with Early Parkinson's Disease (IRB 274317)


Collapse Overview 
Collapse sponsor award id
PD0053


Collapse Biography 

Collapse Time 
Collapse start date
2022-09-13

Collapse end date
2032-09-12